The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC).
H. A. Wakelee
Consultant or Advisory Role - Genentech (U)
Research Funding - Genentech
S. E. Dahlberg
No relevant relationships to disclose
S. M. Keller
No relevant relationships to disclose
D. R. Gandara
Consultant or Advisory Role - Genentech
S. L. Graziano
Research Funding - Genentech
N. B. Leighl
No relevant relationships to disclose
A. A. Adjei
No relevant relationships to disclose
J. H. Schiller
Consultant or Advisory Role - Roche/Genentech
Research Funding - Genentech